News GSK claims first approval for Nucala in COPD GSK gets FDA approval for Nucala in COPD, setting up a marketing tussle with Sanofi/Regeneron's Dupixent.
News GSK sets up Nucala and Dupixent showdown in COPD GSK has said new data leads it to believe Nucala will be "highly competitive" with rival biologic Dupixent in COPD - if it gets approved by the FDA.
Market Access Sanofi's Dupixent gets FDA nod for chronic hives indication Dupixent's seventh indication is chronic hives, where a new treatment hasn't been approved since Novartis's Xolair in 2014
News Can Dupixent plug treatment gap in bullous pemphigoid? The FDA is scheduled to deliver a verdict on Sanofi and Regeneron's Dupixent for rare autoimmune skin disorder bullous pemphigoid in June.
News Sanofi's Dupixent scores double COPD win in US, China Originally anticipated in June, the FDA action stands to make Sanofi and Regeneron's biologic blockbuster even bigger.
News Dupixent delivers in two skin disease trials Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications f
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
